Article
Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
Oncotarget - 21 Aug 2015
Umelo Ijeoma Adaku, De Wever Olivier, Kronenberger Peter, Van Deun Jan, Noor Alfiah, Singh Kshitiz, Teugels Erik, Chen Gang, Bracke Marc, De Grève Jacques
Abstract excerpt
KRAS is a frequently mutated oncogene in lung cancer and among the most refractory to EGFR targeted therapy. Recently, preclinical evidence in pancreatic cancer has demonstrated that mutant KRAS can be regulated by EGFR. However, the distinct correlation between the EGFR/HER family members and mutant KRAS has not been investigated. Here, we show that non-small cell lung cancer cell lines harboring differing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.